Literature DB >> 12667448

Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions.

Philippe Meyer1, Chrisostomos Prodromou, Bin Hu, Cara Vaughan, S Mark Roe, Barry Panaretou, Peter W Piper, Laurence H Pearl.   

Abstract

Activation of client proteins by the Hsp90 molecular chaperone is dependent on binding and hydrolysis of ATP, which drives a molecular clamp via transient dimerization of the N-terminal domains. The crystal structure of the middle segment of yeast Hsp90 reveals considerable evolutionary divergence from the equivalent regions of other GHKL protein family members such as MutL and GyrB, including an additional domain of new fold. Using the known structure of the N-terminal nucleotide binding domain, a model for the Hsp90 dimer has been constructed. From this structure, residues implicated in the ATPase-coupled conformational cycle and in interactions with client proteins and the activating cochaperone Aha1 have been identified, and their roles functionally characterized in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12667448     DOI: 10.1016/s1097-2765(03)00065-0

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  175 in total

Review 1.  HSP90 at the hub of protein homeostasis: emerging mechanistic insights.

Authors:  Mikko Taipale; Daniel F Jarosz; Susan Lindquist
Journal:  Nat Rev Mol Cell Biol       Date:  2010-06-09       Impact factor: 94.444

Review 2.  Getting a grip on non-native proteins.

Authors:  Peter C Stirling; Victor F Lundin; Michel R Leroux
Journal:  EMBO Rep       Date:  2003-06       Impact factor: 8.807

3.  Structural basis for recruitment of the ATPase activator Aha1 to the Hsp90 chaperone machinery.

Authors:  Philippe Meyer; Chrisostomos Prodromou; Chunyan Liao; Bin Hu; S Mark Roe; Cara K Vaughan; Ignacija Vlasic; Barry Panaretou; Peter W Piper; Laurence H Pearl
Journal:  EMBO J       Date:  2004-01-22       Impact factor: 11.598

4.  HSP90 interacts with RAR1 and SGT1 and is essential for RPS2-mediated disease resistance in Arabidopsis.

Authors:  Akira Takahashi; Catarina Casais; Kazuya Ichimura; Ken Shirasu
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

5.  The conserved arginine 380 of Hsp90 is not a catalytic residue, but stabilizes the closed conformation required for ATP hydrolysis.

Authors:  Christian N Cunningham; Daniel R Southworth; Kristin A Krukenberg; David A Agard
Journal:  Protein Sci       Date:  2012-08       Impact factor: 6.725

6.  ATP binding to Hsp90 is sufficient for effective chaperoning of p53 protein.

Authors:  Dawid Walerych; Malgorzata Gutkowska; Marcin P Klejman; Bartosz Wawrzynow; Zuzanna Tracz; Milena Wiech; Maciej Zylicz; Alicja Zylicz
Journal:  J Biol Chem       Date:  2010-08-05       Impact factor: 5.157

Review 7.  Function of cytosolic chaperones in Tom70-mediated mitochondrial import.

Authors:  Anna C Y Fan; Jason C Young
Journal:  Protein Pept Lett       Date:  2011-02       Impact factor: 1.890

8.  Folding and assembly of the large molecular machine Hsp90 studied in single-molecule experiments.

Authors:  Markus Jahn; Johannes Buchner; Thorsten Hugel; Matthias Rief
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-19       Impact factor: 11.205

9.  Hsp90-Tau complex reveals molecular basis for specificity in chaperone action.

Authors:  G Elif Karagöz; Afonso M S Duarte; Elias Akoury; Hans Ippel; Jacek Biernat; Tania Morán Luengo; Martina Radli; Tatiana Didenko; Bryce A Nordhues; Dmitry B Veprintsev; Chad A Dickey; Eckhard Mandelkow; Markus Zweckstetter; Rolf Boelens; Tobias Madl; Stefan G D Rüdiger
Journal:  Cell       Date:  2014-02-27       Impact factor: 41.582

10.  A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.

Authors:  Andrew J Wagner; Rashmi Chugh; Lee S Rosen; Jeffrey A Morgan; Suzanne George; Michael Gordon; Joi Dunbar; Emmanuel Normant; David Grayzel; George D Demetri
Journal:  Clin Cancer Res       Date:  2013-09-17       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.